Clinical study of MAFLD patients measuring circulating MOTS-c levels and correlating them with non-invasive fibrosis scores (FIB-4, NFS) and metabolic syndrome components. Examined whether MOTS-c reflects the severity of liver fibrosis and metabolic dysregulation in fatty liver disease. Establishes that circulating MOTS-c correlates with liver fibrosis severity in MAFLD—positioning serum MOTS-c as a potential non-invasive biomarker of hepatic fibrosis progression that reflects the underlying mitochondrial dysfunction driving steatohepatitis-to-fibrosis transition.
Kirik, A; Dogru, T; Yanik, B; Sen, H; Eroglu, M; Baykan, O; Bozyel, E A; Ergene, A; Selçuk, E; Tasci, I; Sonmez, A